Impact of medical therapy on transurethral resection of the prostate: two decades of change

被引:65
作者
Izard, Jason [1 ]
Nickel, J. Curtis [1 ]
机构
[1] Queens Univ, Dept Urol, Kingston, ON K7L 2V7, Canada
关键词
benign prostatic hyperplasia; transurethral resection of the prostate; lower urinary tract symptoms; medical therapy; alpha blocker; 5-alpha reductase therapy; HYPERPLASIA; FINASTERIDE; SYMPTOMS; MEN;
D O I
10.1111/j.1464-410X.2010.09737.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
OBJECTIVE To examine how the introduction of medical therapy for symptomatic benign prostatic hyperplasia (BPH) might have changed the indications, patient characteristics and outcomes in men undergoing transurethral resection of the prostate (TURP) over two decades (1988-2008). PATIENTS AND METHODS All patients who underwent TURP for symptomatic BPH in a geographically defined area at our institution in 1988 (before the introduction of medical therapy for BPH), 1998 (when medical therapy was becoming an important therapy for BPH), and 2008 (when medical therapy was the primary first line therapy for BPH) were reviewed. We assessed the total number of TURPs, indications for surgery, patient age, health status, weight of resected tissue, and pre- and postoperative events/complications. RESULTS There was a 60% decrease in TURPs from 1988 to 1998 with a moderate increase in number in 2008. Failure of medical therapy was not an indication for TURP in 1988, but was at least one of the indications in 36% and 87% of patients in 1998 and 2008, respectively. There was a substantial rise in the percentage of patients (but not total number or percentage of men at risk for BPH) presenting with acute or chronic urinary retention (AUR or CUR) at the time of their TURP (from 22.9% in 1988 to 42.9% in 2008, and from 14.6% in 1988 to 39.3% in 2008 for AUR and CUR, respectively). There was also a rise in the percentage of patients presenting with preoperative hydronephrosis (1.3% in 1988, 12.5% in 1998, 7.1% in 2008). Inpatient stays decreased (from 4.1 day in 1988 to 2.7 days in 1998, and to 2.1 day in 2008), but the number of patients discharged with a catheter increased over the two decades (from 3.2% in 1988 to 12.5% in 1998, and to 28.6% in 2008). CONCLUSIONS The increasing use of medical therapy as a first line treatment for BPH has resulted in a dramatic decrease in TURPs which, in turn, has been associated with an apparent increase in risk of poor pre- and postoperative outcomes. However, the actual number (either the total number or as a percentage of men at risk for BPH) who have experienced these progression events has not changed and the postoperative outcomes are probably related to earlier catheter removal and hospital discharge. It appears that we are performing TURP on the right patients.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 9 条
[1]
Impact of medical therapy on transurethral resection of the prostate: A decade of change [J].
Borth, CS ;
Beiko, DT ;
Nickel, JC .
UROLOGY, 2001, 57 (06) :1082-1085
[2]
5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A department of Veterans Affairs cooperative study [J].
Flanigan, RC ;
Reda, DJ ;
Wasson, JH ;
Anderson, RJ ;
Abdellatif, M ;
Bruskewitz, RC .
JOURNAL OF UROLOGY, 1998, 160 (01) :12-16
[3]
Health-related quality of life associated with lower urinary tract symptoms in four countries [J].
Girman, CJ ;
Jacobsen, SJ ;
Tsukamoto, T ;
Richard, F ;
Garraway, WM ;
Sagnier, PP ;
Guess, HA ;
Rhodes, T ;
Boyle, P ;
Lieber, MM .
UROLOGY, 1998, 51 (03) :428-436
[4]
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia [J].
McConnell, JD ;
Bruskewitz, R ;
Walsh, P ;
Andriole, G ;
Lieber, M ;
Holtgrewe, HL ;
Albertsen, P ;
Roehrborn, CG ;
Nickel, JC ;
Wang, DZ ;
Taylor, AM ;
Waldstreicher, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09) :557-563
[5]
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].
McConnell, JD ;
Roehrborn, CG ;
Bautista, OM ;
Andriole, GL ;
Dixon, CM ;
Kusek, JW ;
Lepor, H ;
McVary, KT ;
Nyberg, LM ;
Clarke, HS ;
Crawford, ED ;
Diokno, A ;
Foley, JP ;
Foster, HE ;
Jacobs, SC ;
Kaplan, SA ;
Kreder, KJ ;
Lieber, MM ;
Lucia, MS ;
Miller, GJ ;
Menon, M ;
Milam, DF ;
Ramsdell, JW ;
Schenkman, NS ;
Slawin, KM ;
Smith, JA ;
Kusek, JW ;
Nyberg, LM ;
Briggs, JP ;
McConnell, JD ;
Crawford, ED ;
Homan, K ;
Donohue, R ;
Parker, D ;
Easterday, K ;
Robertson, K ;
Kaplan, S ;
Wentland, M ;
Hardy, L ;
Roehrborn, C ;
Ahrens, A ;
McConnell, J ;
Hall, D ;
Cutts, D ;
Carter, S ;
Waldrep, K ;
Schenkman, N ;
Sanetrik, K ;
Sihelnik, S ;
Zorn, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2387-2398
[6]
A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia [J].
Nickel, J. C. ;
Sander, S. ;
Moon, T. D. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (10) :1547-1559
[7]
Reich O, 2008, J UROLOGY, V180, P246, DOI 10.1016/j.juro.2008.03.058
[8]
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study [J].
Roehrborn, Claus G. ;
Siami, Paul ;
Barkin, Jack ;
Damiao, Ronaldo ;
Major-Walker, Kim ;
Nandy, Indrani ;
Morrill, Betsy B. ;
Gagnier, R. Paul ;
Montorsi, Francesco .
EUROPEAN UROLOGY, 2010, 57 (01) :123-131
[9]
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997 [J].
Sarma, AV ;
Jacobson, DJ ;
McGree, ME ;
Roberts, RO ;
Lieber, MM ;
Jacobsen, SJ .
JOURNAL OF UROLOGY, 2005, 173 (06) :2048-2053